China is cautiously recovering from the peak of the COVID-19 outbreak and is moving into a new period of investor-friendly policies aimed at restarting China’s economic engine....more
4/9/2020
/ Artificial Intelligence ,
Best Practices ,
Biologics ,
China ,
Coronavirus/COVID-19 ,
Health and Safety ,
Infectious Diseases ,
Investors ,
Life Sciences ,
Med Tech ,
Medical Devices ,
Pharmaceutical Industry ,
Policies and Procedures ,
Public Health ,
Risk Management ,
Robotics ,
Supply Chain